Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine reported Q1 2026 financial results, significantly narrowing its net loss to $25.0 million ($0.26/share) from $76.1 million in the prior year, while maintaining a cash runway into Q3 2027. The company advanced its lead candidate EDIT-401, with preclinical data showing >90% mean LDL-C reduction and plans to initiate a first-in-human study for HeFH later this year.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.